what else can be used with clonidine to treat opioid addiction

Opioid dose reduction or transition to another opioid therapy often results in uncomfortable signs and symptoms of withdrawal. The severity of these symptoms can fluctuate amid patients, fifty-fifty among those with like body mass index, gender, and dosage.

Several theories have been proposed regarding the contribution of noradrenergic pathways in the expression of opioid withdrawal.ⁱ In the cardinal nervous arrangement, the major clustering of norepinephrine-producing neurons is in the locus coeruleus (LC). Levels of norepinephrine and its metabolites are contradistinct during opioid dependence, resulting in somatic opioid withdrawal symptoms.^ane

Other studies accept suggested that alterations in the density and sensitivity of alpha and beta adrenergic receptors plays a role.ⁱ However, others suggest that a mesolimbic dopaminergic arrangement contributes to opioid withdrawal symptomatology.²

In October, Practical Hurting Management featured an article by Hymes et al on the use of percutaneous electric neurostimulation to treat withdrawal symptoms.³ In this article, the authors examine pharmaceutical ways to benumb withdrawal symptoms. By taking advantage of blastoff- and beta-agonists and antagonist, clinicians can provide faster tapers and less withdrawal symptoms—without calculation a new medication to patients polytherapy.

Symptoms of Opioid Withdrawal

Opioid receptor activation is mediated past 3 different opioid receptors: delta, kappa, and mu. Symptoms of opioid withdrawal may begin 8 to 10 hours after the terminal dose, depending on the half-life and book of distribution of the opioid (Tabular array 1). The dosage form and route of administration tin can influence a drug's pharmacokinetic parameters and the onset of withdrawal following cessation of the drug.

The majority of opioid withdrawal symptoms reflect increased activity of the autonomic nervous arrangement (ANS). While hyperactivity of noradrenergic neurons within the LC has been associated with somatic symptoms of opioid withdrawal, it is also noteworthy that the LC is involved with various neurophysiologic functions,¹ including learning processes and the emotions of feet and fright.

For these reasons, it is idea that excessive activation of the LC noradrenergic neurons not just induces somatic symptoms of opioid withdrawal simply likewise causes the cerebral and emotional problems associated with withdrawal.

The initial stage of withdrawal includes acute symptoms such as lacrimation, rhinorrhea, yawning, and sweating that may final 7 to ten days as well every bit symptoms that occur later, such as restless slumber, weakness, chills, nausea and vomiting, musculus aches, and involuntary movements. The secondary phase of withdrawal includes symptoms such equally hypotension, bradycardia, hypothermia, mydriasis, and decreased responsiveness of the respiratory arrangement to carbon monoxide. The secondary phase tin can last anywhere from 26 to thirty weeks.⁴

The Clinical Opioid Withdrawal Scale (COWS) is a tool used by clinicians to assess the degree of withdrawal a patient is experiencing based on current symptoms.⁵ The COWS reflects the assessment of xi symptoms:, vital signs (pulse), a cursory physical exam (pupil size, sweating, restlessness, runny nose or middle vehement, achiness, GI distress, tremor, yawning, gooseflesh skin) and mental status (irritability or feet).⁵

These symptoms are and so converted into a numeric score based on their severity. These numbers are totaled to class an overall score, from 0 (indicating no withdrawal symptoms) to 48 (the maximum degree of withdrawal symptoms). These scores typically are used to determine whether buprenorphine induction is advisable, with balmy to moderate withdrawal symptoms beingness the ideal time to begin buprenorphine therapy.^five

Treatment of Withdrawal

There are myriad agents that tin exist used to support clinicians in their treatment of patients experiencing opioid withdrawal. The following is a summary of agents that can attenuate withdrawal symptoms (Table 2).

Alpha-1 Antagonists

Administration of the alpha-1 antagonists phentolamine,^vi phenoxybenzamine (Dibenzyline, others),⁶ and prazosin (Minpress, others)⁷ can decrease the occurrence of somatic symptoms associated with opioid withdrawal.

Trazodone (Oleptro, others) is a triazolopyridine derivate that is used as an antidepressant.^eight Trazodone acts as a 5-serotonin (HT)₂ receptor antagonist at high doses and inhibits the reuptake of serotonin at the presynaptic membrane. Trazodone also weakly inhibits alpha-2 adrenergic receptors and strongly inhibits postsynaptic blastoff-ane receptors. Due to its ability to inhibit alpha-1 adrenergic receptors, we postulate that it has a function in opioid withdrawal. Interestingly, trazodone has been shown to bind to opioid receptors besides, but only at high concentrations.⁸

When studied in mice, trazodone was constitute to induce potent mu-ane and mu-2 opioid receptor–mediated pain relief. Schreiber et al evaluated the effects of trazodone on opioid withdrawal symptoms in morphine-dependent mice who were receiving a loftier dose of naloxone.⁹ They evaluated the intensity of withdrawal symptoms using three different behavioral measurements: rearing, jumping, and grooming and found that calculation trazodone to naloxone in morphine-dependent mice effectively decreased opioid-withdrawal intensity.^nine

Alpha-2 Agonists

Another amanuensis that is commonly used to attenuate opioid withdrawal is clonidine (Catapres, Kapvay, others). The use of clonidine for opioid withdrawal originally was proposed by DeStefano et al.¹⁰ In add-on, studies accept revealed that clonidine plays a role in reducing the negative motivational aspects of opioid withdrawal.¹¹

A contempo review article by Gowing et al evaluated the evidence for blastoff-2 adrenergic agonists in the management of withdrawal symptoms in people who are physically dependent on opioids.¹² The review evaluated 25 randomized command trials consisting of i,668 opioid-dependent patients who were being treated with either clonidine, lofexidine, guanfacine (Tenex, Intuniv, others), or tizanidine (Zanaflex, others). Twelve studies compared blastoff-adrenergic agonists with decreasing doses of methadone (Dolophine, Methadose, others), 5 studies compared alpha-2 agonists with placebo, 4 studies compared the report drug with drugs used for specific symptom control in withdrawal, and 5 studies compared different alpha-2 adrenergic agonists to each other. Treatment elapsing averaged i to 2 weeks (shortest elapsing was three days, and longest elapsing was thirty days).

The review showed no difference in opioid withdrawal symptoms betwixt those receiving fundamental alpha-2 adrenergic agonists and those treated with decreasing doses of methadone.¹² The take chances of completing treatment likewise was similar with alpha-2 adrenergic agonists and decreasing doses of methadone. However, the duration of treatment was longer with methadone. There were fewer adverse effects with methadone withdrawal signs and symptoms occurred before in patients taking blastoff-adrenergic agonists. Of annotation, clonidine and lofexidine were more effective than placebo in managing withdrawal from heroin or methadone and were more likely to be associated with treatment completion than placebo. The studies conclude that alpha-2 adrenergic agonists may be an culling in treating opioid withdrawal.¹²

Sos et al evaluated the effects of the alpha-2 adrenergic agonist tizanidine in patients suffering from opioid addiction.¹³ In this study, 26 intravenous heroin users were divided into 2 groups; each group had the usual detoxification treatment, only patients in the experimental group were given tizanidine 8 mg three times daily. A subjective scale was used to determined severity of withdrawal using 7 key withdrawal symptoms (sweating, nervousness, insomnia, tremor, diarrhea, muscle pain, and drug craving). The results of the study showed that tizanidine treatment decreased the intensity of withdrawal symptoms and may have potential do good in treating opioid withdrawal.^xiii

Although at that place are no studies to propose that methyldopa is useful in the prevention of withdrawal, because it is a centrally acting blastoff-ii agonist we could postulate that information technology would provide some benefit in this setting.¹²

Beta-1 Antagonists And Beta-2 Antagonists

Propranolol (Inderal, InnoPran Forty, others) and atenolol (Tenormin, others) accept been reported to reduce somatic signs of spontaneous opioid withdrawal and naloxone-precipitated opioid abstinence.¹⁴ Information technology is theorized that beta blockers tin can accept these effects because they cake the noradrenergic hyperactivity associated with supersensitive beta-adrenergic receptors that issue from adaptive changes induced by chronic opioid exposure.^15-17 Somatic symptoms, including jumping and wet dog shakes, were both blocked by beta-1 antagonists, whereas beta-2 antagonists accept been shown to suppress the incidence of wet canis familiaris shakes only.^fourteen

Propranolol and atenolol have been shown to reduce withdrawal-induced anxiety in animals.^15,16 Addicts take reported that anxiety associated with opioid withdrawal often returns when they are in an environment that is associated with drug apply. Harris and Aston-Jones conducted a study to investigate whether propranolol and atenolol reduced somatic symptoms and whether the medications reduced place aversion in opioid-abstinent rats.^15,xvi The well-nigh common somatic symptoms included moisture dog shakes, teeth chatter, writhing, and phonation upon affect. Place aversion was tested by injecting the rats with naloxone in one area of the cage and then observing whether the rats avoided that area. The investigators found that beta-adrenergic antagonists reduced somatic symptoms and alleviated withdrawal-induced feet.

Beta receptors have a office in promoting consolidation and retrieval of retention; thus, in theory, blocking this pathway with a beta-adrenergic antagonist would prevent such memories from forming.¹⁷ Animal studies accept suggested that propranolol can disrupt retention reconsolidation that previously had been associated with rewarding medications such equally morphine.^17-xix Such results imply that by preventing the retention of the rewarding furnishings of the medication, propranolol could exist effective for preventing relapse in addicts.

Although a prior study by Robinson et al showed that propranolol disrupted memory reconsolidation associated with morphine,¹⁸ when they tested this theory in rats, they establish that in a setting of exposure to high doses of morphine, propranolol was not able to disrupt memory reconsolidation.¹⁹ This study indicates that chronic exposure to morphine markedly alters the effects of propranolol as a reconsolidation blocking treatment.¹⁹

NMDA Receptor Antagonists

Some evidence suggests that another machinery responsible for tolerance to and withdrawal from opioids involves activation of Northward-methyl-D-aspartase (NMDA) receptors. Thus, it has been theorized that NMDA antagonists may decrease withdrawal symptoms.²⁰

Bisaga et al demonstrated that the NMDA-receptor antagonist memantine (Namenda, others) decreased naloxone-induced symptoms of withdrawal in heroin-addicted patients.²¹ Amantadine, another NMDA antagonist with dopaminergic, adrenergic, and serotonergic properties (MAO-A inhibition), likewise has been theorized to have efficacy in the treatment of opioid-withdrawal symptoms. Amiri et al constitute that amantadine plus clonidine was superior to clonidine alone in decision-making opioid-withdrawal symptoms for a elapsing of iii days in a study involving 69 patients.²² The machinery of activity may exist due to NMDA-receptor inhibition and MAO inhibition, which cause an increase in beta-endorphins. Amiri et al showed a tendency for increased withdrawal symptoms on day 3^; thus, studies washed with amantadine for a longer duration are warranted.

The antitussive dextromethorphan is another agent that, theoretically, tin can provide benefit for patients experiencing opioid withdrawal, based on its ability to inhibit NMDA receptors. Dextromethorphan is metabolized to dextrophan, the pharmacologic activeness of which is primarily at the NMDA receptor. (Dextromethorphan binds to NMDA bounden sites with a 10-fold lower affinity than dextrophan.)²³

In a randomized clinical trial involving 48 heroin addicts, dextromethorphan showed do good in attenuating withdrawal symptoms. Dextromethorphan combined with diazepam (Valium, others) had greater efficacy compared with diazepam and chlorpromazine combined.²⁴

However, Rosen et al plant that oral dextromethorphan (60 mg, 120 mg, or 240 mg) did non attenuate withdrawal symptoms in 11 subjects who experienced naloxone-precipitated withdrawal after beingness stabilized on oral methadone 25 mg per day.²³ Subjects received challenges with 0.four mg of intramuscular naloxone on 3 dissimilar days and were randomized to receive either dextromethorphan or placebo. Patients taking dextromethorphan showed no departure in withdrawal symptoms compared with patients taking placebo.²³

Bisaga et al showed beneficial data for withdrawal with dextromethorphan in 6 male patients who were daily heroin users.²⁵ The patients in this trial were hospitalized during the report, and all received 75 mg of dextromethorphan v times per day (no other medications were given too hydroxyzine [Vistaril, others], acetaminophen [Tylenol, others], and ibuprofen [Advil, Motrin, others]). 2 patients dropped out of the study, but the iv patients who completed the study reported a subjective difference from previous detoxification with methadone; they all had a rapid and thorough subtract in signs, symptoms, and peckish associated with opioids by the fourth mean solar day of treatment. Patients received handling for an average of vi days and were discharged later beingness free from medication for one twenty-four hour period. Results of this trial point that dextromethorphan may be an inpatient treatment choice in patients suffering from opioid withdrawal.²⁵

Of note, efficacy in treating opioid withdrawal symptoms can be expected from dextromethorphan due to its NMDA-adversary backdrop, not due to its effects every bit an opioid agonist. Dextromethorphan's binding affinity to mu opioid receptors is 6,000 times less than that of morphine; thus, we would non see much efficacy to diminish withdrawal symptoms due to its mu opioid–receptor action.

Orphenadrine (Norflex, others), a ordinarily used muscle relaxant, is an anticholinergic medication with NMDA-antagonist backdrop. Theoretically, orphenadrine tin can be used for opioid withdrawal due to its ability to inhibit NMDA receptors.²⁶ Although there take been no studies conducted to substantiate the role of orphenadrine in opioid withdrawal, anecdotal reports have noted do good from its employ to mitigate such symptoms.

Serotonergic and Norepinephrine Reuptake Inhibitors

Venlafaxine (Effexor, others) is a novel antidepressant that blocks reuptake of norepinephrine and serotonin. It has been postulated to mitigate opioid withdrawal due to its serotonin reuptake–blocking properties. In a study by Lu et al, rats treated with chronic morphine were pretreated with venlafaxine or not given anything before administration of naloxone.²⁷ Pretreatment significantly attenuated the rats' symptoms of morphine withdrawal, including jumping, writhing, shaking, exploring, lacrimation, piloerection, irritability, and diarrhea. Venlafaxine also attenuated morphine-induced reacquisition of conditioned place preference in these rats. Nevertheless, because in that location is express evidence to suggest that the serotonergic system is involved in opioid withdrawal, more studies are warranted to decide if the serotonergic properties of venlafaxine contribute to the attenuation of withdrawal symptoms.

Although there is limited evidence for the role of serotonergic neurotransmission in opioid dependence and withdrawal, the selective serotonin reuptake inhibitors (SSRI) fluvoxamine and sertraline (Zoloft, others) have been shown to decrease the intensity of physical signs of naloxone-induced opioid withdrawal.²⁸ In an experiment conducted past Gray, naloxone increased norepinephrine levels in the hippocampus of morphine-dependent rats 20 minutes after assistants, and withdrawal-induced physical behaviors were apparent five minutes after injection.²⁸ Study animals were given either fluvoxamine or sertraline, either acutely (after discontinuation of 8 days of therapy with morphine and right before naloxone administration) or chronically (afterwards daily morphine doses for 8 days). Chronic assistants of both SSRIs reduced the severity of naloxone-precipitated opioid withdrawal syndrome and prevented naloxone-precipitated increases in hippocampal levels of norepinephrine.

All the same, acute assistants did not prevented naloxone-precipitated increases in norepinephrine in the hippocampus. Acute assistants of SSRIs only reduced the intensity of physical symptoms of naloxone-precipitated opioid withdrawal.²⁸ The main finding of the study was that fluvoxamine given once daily following morphine prevented an increase in norepinephrine levels and the physical behaviors of opioid withdrawal, and reduced levels of norepinephrine in the hippocampus of morphine-dependent rats.²⁸

Theories about the ability of SSRIs to meliorate symptoms of opioid withdrawal suggest that increased serotonin in the synaptic cleft tin can increment the inhibitory tone of the LC, causing lower levels of noradrenergic activeness inside the LC.²⁸ Some other hypothesis suggests that SSRIs may be involved in increasing endogenous opioid levels, which tin cause a decrease in norepinephrine levels.^28,29

Mirtazapine (Remeron, others) is an antidepressant with noradrenergic and serotonergic properties. More specifically, mirtazapine is a potent presynaptic alpha-2 receptor antagonist, v-HT_one receptor agonist, and five-HT_two and 5-HT₃ adversary. A report conducted by Kang et al tested the acute and chronic effects of mirtazapine on rats that were given morphine for 10 days.³⁰ The astute effects of mirtazapine were observed by administering mirtazapine fifteen minutes before naloxone. The chronic furnishings of mirtazapine were tested past administering mirtazapine xv minutes before daily doses of morphine. The experiment recorded 8 behaviors (moisture dog shakes, digging, teeth chattering, rearing, grooming, chewing, scratching, and escape omnipresence) over a flow of xxx minutes.

Overall, the results of the study showed that chronic mirtazapine can reduce the severity of withdrawal symptoms, inhibit the peckish for morphine, and may decrease the rewarding furnishings of morphine in rats.^thirty Also, mirtazapine caused pronounced top in dopamine levels. Kang et al proposed that mirtazapine increases levels of dopamine past inhibiting alpha-2 adrenoceptors in the cerebral cortex and by blocking 5-HTc₂ receptors that generally block prefrontal cortex release of dopamine. The rise in dopamine is the suggested neurobiological machinery of mirtazapine'south action for reducing acute withdrawal symptoms and inhibiting opioid craving in rats. More studies are warranted to explore the function of mirtazapine in the handling of opioid dependence and withdrawal in humans.³⁰

Dopaminergic Agonists And Antagonists

At that place are contradictory data on the part of dopamine agonists and antagonists in morphine withdrawal.^31,32 For example, amphetamine, apomorphine, and levodopa have been shown to increase assailment in rats undergoing morphine withdrawal^33,34 but quinpirole decreases assailment associated with morphine withdrawal. Furthermore, Harris and Aston-Jones found that activation of D₂ dopaminergic receptors inside the NAc prevented some of the somatic symptoms of opioid withdrawal.³⁵

Radhke and Gewirtz examined the effects of dopamine agonists on withdrawal-induced anxiety following spontaneous withdrawal from acute morphine exposure.³⁶ They examined the furnishings of intracerebrally infused dopamine-receptor agonists on the potentiation of audio-visual startle reflex, which likely represent the feet-like component of withdrawal. The experiments used 2 dopamine receptor agonists, SKF82958 (D_ane receptor agonist) and quinpirole (D₂ receptor agonist), and randomly injected either medication during morphine withdrawal in rats. The study found that activation of D_one- and D_2-like receptors attenuated opioid withdrawal–induced feet and, thus, support the theory that diminishing action at both D_one- and D_2-like receptors have a role in the expression of opioid withdrawal.³⁶

From a pharmacologic perspective, since opioid withdrawal is associated with a reduction in the release of dopamine along the mesolimbic pathway, dopamine agonists take shown some benefit for opioid withdrawal. Counterintuitive to this is the fact that some dopamine antagonists, in particular the butyrophenones haloperidol (Haldol, others) and droperidol, take some benefit in withdrawal too.³⁷ Both butyrophenone antipsychotics cake postsynaptic mesolimbic dopaminergic D_ii receptors in the brain and reduce dopaminergic neurotransmission in the iv dopaminergic pathways.

Haloperidol has been shown to markedly subtract morphine withdrawal-induced aggression.³⁷ Rodriguez-Arias et al revealed that aggressive behavior in rats decreased when they were administered haloperidol during either naloxone-precipitated or spontaneous withdrawal. This written report suggested that anti-aggressive effects of haloperidol were more than pronounced in naloxone-precipitated withdrawal than in spontaneous withdrawal.³⁷

Sivolap and Savenkov examined 197 patients who were treated with haloperidol and droperidol following opioid withdrawal.³⁸ They found that withdrawal-induced psychosis was relieved with droperidol and haloperidol, and these two agents were particularly helpful in the acute phase of withdrawal. Although the exact machinery through which these agents attenuate symptoms of withdrawal are unclear, it is evident that these agents have some benefit in opioid withdrawal.³⁸

Miscellaneous

Bupropion (Aplenzin, Buproban, others), a norepinephrine and dopamine reuptake inhibitor, has shown some benefit in opioid withdrawal. Joshi et al studied the effects of bupropion on morphine tolerance and dependence in mice.³⁹ They gave mice bupropion therapy (ii or 5 mg/d) with morphine for 10 days. When naloxone was administered, the mice treated with bupropion had less withdrawal-induced jumps. Furthermore, acute administration of bupropion on day ten decreased the incidence of naloxone-precipitated withdrawal jumps without causing tolerance to the analgesic effect. The results of this study suggest that buproprion may have potential in opioid withdrawal.

Although the exact mechanism for bupropion's efficacy in opioid withdrawal is unknown, its power to decrease reuptake of dopamine may contribute to attenuation of withdrawal symptoms.

Summary

A person'southward power to tolerate a rapid opioid taper and substantial dose reductions when converting to other opioids tin, in large part, depend on their concomitant medical therapies. These therapies, which may have been prescribed for any number of disorders, can directly or indirectly impact the sympathetic and parasympathetic nervous systems. All of these factors should be carefully considered when tapering or switching opioids.

Last updated on: January three, 2019

mccrackenwitich.blogspot.com

Source: https://www.practicalpainmanagement.com/treatments/pharmacological/opioids/opioid-withdrawal-new-look-medication-options